Overall, this audit indicates considerable variation in the U.K. management of children with psoriasis when compared with the NICE guidelines.[1] Generally, the choice of topical agent appears appropriate, and the clinical indications for initiating second- and third-line treatment are clearly documented. However, formal assessment of disease severity and impact does not form part of regular clinical practice with the exception of those patients with more severe disease in which biological therapies are being considered.